Ovarian cancer cost-effectiveness of therapy

Jump to: navigation, search

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer cost-effectiveness of therapy

CDC on Ovarian cancer cost-effectiveness of therapy

Ovarian cancer cost-effectiveness of therapy in the news

Blogs on Ovarian cancer cost-effectiveness of therapy

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: , Huda A. Karman, M.D.

Overview

The management of ovarian cancer is composed of surgery and chemotherapy that can be either adjuvant or neoadjuvant depending on the stage and grade of the tumor and on the condition and function of the patient. Bevacizumab in addition to chemotherapy is a cost-effective alternative for ovarian cancer patients who are at high risk of progression.

Cost-effectiveness of therapy

References

  1. Martín-Cameá, María; Delgado-Sánchez, Elsa; Piñera, Antonio; Diestro, Maria Dolores; De Santiago, Javier; Zapardiel, Ignacio (2016). "The role of surgery in advanced epithelial ovarian cancer". ecancermedicalscience. 10. doi:10.3332/ecancer.2016.666. ISSN 1754-6605.
  2. Duong, M.; Wright, E.; Martin-Nunez, I.; Yin, L.; Ghatage, P.; Fung-Kee-Fung, M. (2016). "The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada". Current Oncology. 23 (5): 461. doi:10.3747/co.23.3139. ISSN 1718-7729.

Linked-in.jpg